4E1RCatDual inhibitor of eIF4E:eIF4G and eIF4E:4E-BP1 interaction CAS# 328998-25-0 |
- Cercosporamide
Catalog No.:BCC2438
CAS No.:131436-22-1
- 4EGI-1
Catalog No.:BCC5337
CAS No.:315706-13-9
- KC7F2
Catalog No.:BCC2434
CAS No.:927822-86-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 328998-25-0 | SDF | Download SDF |
PubChem ID | 16195554 | Appearance | Powder |
Formula | C28H18N2O6 | M.Wt | 478.45 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 5.4 mg/mL (11.29 mM; Need warming) | ||
Chemical Name | 4-[(3E)-3-[[5-(4-nitrophenyl)furan-2-yl]methylidene]-2-oxo-5-phenylpyrrol-1-yl]benzoic acid | ||
SMILES | C1=CC=C(C=C1)C2=CC(=CC3=CC=C(O3)C4=CC=C(C=C4)[N+](=O)[O-])C(=O)N2C5=CC=C(C=C5)C(=O)O | ||
Standard InChIKey | BBQRBOIMSKMFFO-LTGZKZEYSA-N | ||
Standard InChI | InChI=1S/C28H18N2O6/c31-27-21(16-24-14-15-26(36-24)19-6-12-23(13-7-19)30(34)35)17-25(18-4-2-1-3-5-18)29(27)22-10-8-20(9-11-22)28(32)33/h1-17H,(H,32,33)/b21-16+ | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Inhibitor of protein translation; blocks eIF4E:eIF4G and eIF4E:4E-BP1 interaction. Prevents assembly of the eIF4F complex and inhibits cap-dependent translation (IC50 ~4 μM). Exhibits chemosensitizing properties. |
4E1RCat Dilution Calculator
4E1RCat Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.0901 mL | 10.4504 mL | 20.9008 mL | 41.8017 mL | 52.2521 mL |
5 mM | 0.418 mL | 2.0901 mL | 4.1802 mL | 8.3603 mL | 10.4504 mL |
10 mM | 0.209 mL | 1.045 mL | 2.0901 mL | 4.1802 mL | 5.2252 mL |
50 mM | 0.0418 mL | 0.209 mL | 0.418 mL | 0.836 mL | 1.045 mL |
100 mM | 0.0209 mL | 0.1045 mL | 0.209 mL | 0.418 mL | 0.5225 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
4E1RCat is a dual inhibitor of eIF4E:4E-BP1 and eIF4E:eIF4G interaction, and inhibits the binding of eIF4G to eIF4E with IC50 of 3.2 μM.
The complexity of eIF4A, eIF4E and eIF4G together forms the eIF4F, the eukaryotic initiation factor, which stimulates the loading of ribosomes onto mRNA templates in protein synthesis. The inhibition of this cap-dependent translation is associated with cancer initiation and progression [1].
4E1RCat prevents assembly of the eIF4F complex and inhibits cap-dependent translation [1]. 4E1RCat significantly inhibited 5′-cap-mediated mCherry synthesis while had little effect on the IRES-mediated DIAPH1-HA synthesis, which confirmed the specific inhibitory effect of 4E1RCat on 5′-cap-mediated translation [2].
References:
[1]. Cencic R, Hall DR, Robert F, et al. Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc Natl Acad Sci, 2011, 108(3): 1046-1051.
[2]. Liao G, Liu G. Immediate translation of Formin DIAPH1 mRNA after its exiting the nucleus is required for its perinuclear localization in fibroblasts. PLoS One, 2013, 8(6): e68190.
- C646
Catalog No.:BCC4546
CAS No.:328968-36-1
- pep2-SVKI
Catalog No.:BCC5784
CAS No.:328944-75-8
- Tildipirosin
Catalog No.:BCC5478
CAS No.:328898-40-4
- De-O-methyllasiodiplodin
Catalog No.:BCN7187
CAS No.:32885-82-8
- Lasiodiplodin
Catalog No.:BCN4770
CAS No.:32885-81-7
- Cajanin
Catalog No.:BCN5249
CAS No.:32884-36-9
- Benzylamine hydrochloride
Catalog No.:BCN6908
CAS No.:3287-99-8
- AG-14361
Catalog No.:BCC2209
CAS No.:328543-09-5
- GlyH-101
Catalog No.:BCC4104
CAS No.:328541-79-3
- Lannaconitine
Catalog No.:BCN2504
CAS No.:32854-75-4
- (H-Cys-OMe)2.2HCl
Catalog No.:BCC2916
CAS No.:32854-09-4
- Coniferyl alcohol
Catalog No.:BCN4651
CAS No.:32811-40-8
- Norepinephrine hydrochloride
Catalog No.:BCC5133
CAS No.:329-56-6
- DL-Adrenaline
Catalog No.:BCC4318
CAS No.:329-65-7
- PMSF
Catalog No.:BCC1229
CAS No.:329-98-6
- Withanolide A
Catalog No.:BCN8010
CAS No.:32911-62-9
- SANT-2
Catalog No.:BCC3937
CAS No.:329196-48-7
- Quetiapine hydroxy impurity
Catalog No.:BCN5340
CAS No.:329216-67-3
- Boc-His(Trt)-OH
Catalog No.:BCC3403
CAS No.:32926-43-5
- Sanggenol L
Catalog No.:BCN3692
CAS No.:329319-20-2
- 7-O-Methylaloeresin A
Catalog No.:BCN2849
CAS No.:329361-25-3
- FPR A14
Catalog No.:BCC7498
CAS No.:329691-12-5
- Pinoresinol diacetate
Catalog No.:BCN5250
CAS No.:32971-25-8
- 2-Acetyl-3-ethylpyrazine
Catalog No.:BCC8512
CAS No.:32974-92-8
Crimean-Congo Hemorrhagic Fever Virus Nucleocapsid Protein Augments mRNA Translation.[Pubmed:28515298]
J Virol. 2017 Jul 12;91(15). pii: JVI.00636-17.
Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne Nairovirus of the Bunyaviridae family, causing severe illness with high mortality rates in humans. Here, we demonstrate that CCHFV nucleocapsid protein (CCHFV-NP) augments mRNA translation. CCHFV-NP binds to the viral mRNA 5' untranslated region (UTR) with high affinity. It facilitates the translation of reporter mRNA both in vivo and in vitro with the assistance of the viral mRNA 5' UTR. CCHFV-NP equally favors the translation of both capped and uncapped mRNAs, demonstrating the independence of this translation strategy on the 5' cap. Unlike the canonical host translation machinery, inhibition of eIF4F complex, an amalgam of three initiation factors, eIF4A, eIF4G, and eIF4E, by the chemical inhibitor 4E1RCat did not impact the CCHFV-NP-mediated translation mechanism. However, the proteolytic degradation of eIF4G alone by the human rhinovirus 2A protease abrogated this translation strategy. Our results demonstrate that eIF4F complex formation is not required but eIF4G plays a critical role in this translation mechanism. Our results suggest that CCHFV has adopted a unique translation mechanism to facilitate the translation of viral mRNAs in the host cell cytoplasm where cellular transcripts are competing for the same translation apparatus.IMPORTANCE Crimean-Congo hemorrhagic fever, a highly contagious viral disease endemic to more than 30 countries, has limited treatment options. Our results demonstrate that NP favors the translation of a reporter mRNA harboring the viral mRNA 5' UTR. It is highly likely that CCHFV uses an NP-mediated translation strategy for the rapid synthesis of viral proteins during the course of infection. Shutdown of this translation mechanism might selectively impact viral protein synthesis, suggesting that an NP-mediated translation strategy is a target for therapeutic intervention against this viral disease.
CDK1 substitutes for mTOR kinase to activate mitotic cap-dependent protein translation.[Pubmed:25883264]
Proc Natl Acad Sci U S A. 2015 May 12;112(19):5875-82.
Mitosis is commonly thought to be associated with reduced cap-dependent protein translation. Here we show an alternative control mechanism for maintaining cap-dependent translation during mitosis revealed by a viral oncoprotein, Merkel cell polyomavirus small T (MCV sT). We find MCV sT to be a promiscuous E3 ligase inhibitor targeting the anaphase-promoting complex, which increases cell mitogenesis. MCV sT binds through its Large T stabilization domain region to cell division cycle protein 20 (Cdc20) and, possibly, cdc20 homolog 1 (Cdh1) E3 ligase adapters. This activates cyclin-dependent kinase 1/cyclin B1 (CDK1/CYCB1) to directly hyperphosphorylate eukaryotic initiation factor 4E (eIF4E)-binding protein (4E-BP1) at authentic sites, generating a mitosis-specific, mechanistic target of rapamycin (mTOR) inhibitor-resistant delta phospho-isoform not present in G1-arrested cells. Recombinant 4E-BP1 inhibits capped mRNA reticulocyte translation, which is partially reversed by CDK1/CYCB1 phosphorylation of 4E-BP1. eIF4G binding to the eIF4E-m(7)GTP cap complex is resistant to mTOR inhibition during mitosis but sensitive during interphase. Flow cytometry, with and without sT, reveals an orthogonal pH3(S10+) mitotic cell population having higher inactive p4E-BP1(T37/T46+) saturation levels than pH3(S10-) interphase cells. Using a Click-iT flow cytometric assay to directly measure mitotic protein synthesis, we find that most new protein synthesis during mitosis is cap-dependent, a result confirmed using the eIF4E/4G inhibitor drug 4E1RCat. For most cell lines tested, cap-dependent translation levels were generally similar between mitotic and interphase cells, and the majority of new mitotic protein synthesis was cap-dependent. These findings suggest that mitotic cap-dependent translation is generally sustained during mitosis by CDK1 phosphorylation of 4E-BP1 even under conditions of reduced mTOR signaling.
Regulation of cardiac expression of the diabetic marker microRNA miR-29.[Pubmed:25062042]
PLoS One. 2014 Jul 25;9(7):e103284.
Diabetes mellitus (DM) is an independent risk factor for heart disease and its underlying mechanisms are unclear. Increased expression of diabetic marker miR-29 family miRNAs (miR-29a, b and c) that suppress the pro-survival protein Myeloid Cell Leukemia 1(MCL-1) is reported in pancreatic beta-cells in Type 1 DM. Whether an up-regulation of miR-29 family miRNAs and suppression of MCL-1 (dysregulation of miR-29-MCL-1 axis) occurs in diabetic heart is not known. This study tested the hypothesis that insulin regulates cardiac miR-29-MCL-1 axis and its dysregulation correlates with DM progression. In vitro studies with mouse cardiomyocyte HL-1 cells showed that insulin suppressed the expression of miR-29a, b and c and increased MCL-1 mRNA. Conversely, Rapamycin (Rap), a drug implicated in the new onset DM, increased the expression of miR-29a, b and c and suppressed MCL-1 and this effect was reversed by transfection with miR-29 inhibitors. Rap inhibited mammalian target of rapamycin complex 1 (mTORC1) signaling in HL-1 cells. Moreover, inhibition of either mTORC1 substrate S6K1 by PF-4708671, or eIF4E-induced translation by 4E1RCat suppressed MCL-1. We used Zucker diabetic fatty (ZDF) rat, a rodent model for DM, to test whether dysregulation of cardiac miR-29-MCL-1 axis correlates with DM progression. 11-week old ZDF rats exhibited significantly increased body weight, plasma glucose, insulin, cholesterol, triglycerides, body fat, heart weight, and decreased lean muscle mass compared to age-matched lean rats. Rap treatment (1.2 mg/kg/day, from 9-weeks to 15-weeks) significantly reduced plasma insulin, body weight and heart weight, and severely dysregulated cardiac miR-29-MCL1 axis in ZDF rats. Importantly, dysregulation of cardiac miR-29-MCL-1 axis in ZDF rat heart correlated with cardiac structural damage (disorganization or loss of myofibril bundles). We conclude that insulin and mTORC1 regulate cardiac miR-29-MCL-1 axis and its dysregulation caused by reduced insulin and mTORC1 inhibition increases the vulnerability of a diabetic heart to structural damage.